| Self-sufficiency of NIP Vaccines |
DTaP |
Securing Acellular pertussis (aP) for the domestic supply of DTaP and combination vaccine |
Phase 2 |
| Japanese Encephalitis |
Improving the vaccine safety by replacing the production process |
| Hepatitis A |
Recent outbreak and the need for stable supply of low-cost vaccine |
| Human Papilloma Virus |
Head and neck cancer indications in addition to cervical cancer |
| Vaccines of Global Unmet Need |
SFTS |
- Increase in outbreak
- High mortality rate
- Lack of treatment or prevention
|
| Norovirus gastroenteritis |
- Frequent outbreaks in group facilities
- No commercial vaccine available
|
| Next-generation Tuberculosis |
- Ranked No. 1 mortality rate among OECD countries
- Efficacy issue of BCG and need for booster vaccine for adults
|
| Hand-Foot-and-Mouth Disease |
- Frequent outbreaks for infants and children
- No commercial vaccine available
|
| Universal Influenza |
- Vaccine mismatch and lack of efficacy of the seasonal vaccine
- Need for cross-protective vaccines against drift and shift strains
|
Phase 1 |
| Dengue Fever |
- Increased inflow of patients
- Vaccine safety concern due to ADE (antibody-dependent enhancement)
|
Non clinical |
| Respiratory Syncytial Virus |
- High mortality rate for infants and toddlers
- No commercial vaccine available
|
| Vaccine platform technologies for emerging viral diseases |
Increase of pandemic outbreak and the need for the speedy delivery of vaccines |
Candidate Verification |
| Vaccine Platform Technology |
Novel Vaccine Adjuvant |
- Increase vaccine efficacy
- Dose sparing effect
- Applicable to a variety of vaccines
|
| Vaccine Delivery System |
Platform for the speedy supply, non-invasive route of immunization, and augmenting vaccine efficacy |
